Skip to main content
Clinical Trials/NCT04730297
NCT04730297CompletedPhase 4

Comparative Analgesic Effects of Preoperative Administration of Paracetamol (Acetominophen) 500 mg Plus Codeine 30 mg and Ibuprofen 400 mg on Pain After Third Molar Surgery

University of Roma La Sapienza1 site in 1 country120 target enrollmentStarted: January 1, 2018Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Sponsor
Enrollment
120
Locations
1
Primary Endpoint
Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

Study Overview

Brief Summary

To compare analgesic effects of preoperative administration of paracetamol 500 milligram plus codeine 30 milligram in single-tablet and effervescent formulation to ibuprofen 400 milligram, and placebo in the management of moderate to severe postoperative pain after mandibular third molar surgery.

Detailed Description

Materials and methods

One hundred twenty healthy outpatients aged 15 to 29 years undergoing surgical removal of one bony impacted mandibular third molar were enrolled in this, single-center, prospective, randomized, triple-blind parallel-group, placebo-controlled, clinical trial. Study participants were randomly assigned to three treatment arms. According to the concealed allocation, each patient 30 minutes before surgery received paracetamol 500 mg plus codeine 30 mg (group A), ibuprofen 400 mg (group B) or placebo (group C). Rescue therapy allowed in the postoperative period was paracetamol 500 mg plus codeine 30 mg in groups A and C and ibuprofen 400 mg in group B. Patients recorded on Numerical Rating Scale-11 (NRS-11) the pain intensity, total number of postoperative-supplement medications and time of the first intake, until 12-hours after surgery and over extra two days

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Triple (Participant, Care Provider, Investigator)

Eligibility Criteria

Ages
15 Years to 29 Years (Child, Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • healthy status (ASA class I);
  • nonsmoker;
  • not pregnant or breastfeeding;
  • no medication consumption in the past 21 days;
  • good oral hygiene;
  • bony impaction of one mandibular third molars;
  • the presence of the first and second molars;
  • compliance to cooperate with the research protocol.

Exclusion Criteria

  • chronic systemic disease;
  • medications with potential interaction to paracetamol-codeine or ibuprofen;
  • a history of intolerance or hypersensitivity to the study drugs;
  • any pre-existing pain and acute inflammatory or infectious conditions; - inability to understand or perform the study procedure.

Arms & Interventions

Paracetamol/codeine Group A

Active Comparator

analgesic group preoperative oral dose of paracetamol 500 mg plus codeine 30 mg

Intervention: paracetamol 500 mg plus codeine 30 mg preoperative administration (Drug)

Ibuprofen Group B

Active Comparator

analgesic group preoperative oral dose of ibuprofen 400 mg

Intervention: ibuprofen 400 mg preoperative administration (Drug)

Placebo Group C

Placebo Comparator

Placebo group preoperative placebo

Intervention: Placebo oral tablet preoperative administration (Drug)

Outcomes

Primary Outcomes

Pain measurement assessed with the Numerical Rating Scale-11 (NRS-11)

Time Frame: All study participants were asked to record the pain intensity score at 11:00 pm during the 3th day after surgery]

In stage 1, the objective was to compare the efficacy on pain and tolerability of a single dose of paracetamol plus codeine, ibuprofen, or placebo in the operative day.

Secondary Outcomes

  • Number of patients requiring rescue therapy(until 12-hours after surgery and over extra two days)
  • first postoperative use of analgesics(until 12-hours after surgery)
  • total postoperative use of analgesics(until 12-hours after surgery and over extra two days)

Investigators

Sponsor
University of Roma La Sapienza
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Maria Paola Cristalli

Associate Professor DDS, PhD

University of Roma La Sapienza

Study Sites (1)

Loading locations...

Similar Trials